<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ban GI</submitter><funding>National Cancer Institute</funding><funding>NCI NIH HHS</funding><funding>NIAMS NIH HHS</funding><funding>NIH</funding><pagination>110187</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11233968</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>27(7)</volume><pubmed_abstract>Intratumoral heterogeneity is common in cancer, particularly in sarcomas like undifferentiated pleomorphic sarcoma (UPS), where individual cells demonstrate a high degree of cytogenic diversity. Previous studies showed that a small subset of cells within UPS, known as the metastatic clone (MC), as responsible for metastasis. Using a CRISPR-based genomic screen &lt;i>in-vivo&lt;/i>, we identified the COMPASS complex member &lt;i>Setd1a&lt;/i> as a key regulator maintaining the metastatic phenotype of the MC in murine UPS. Depletion of &lt;i>Setd1a&lt;/i> inhibited metastasis development in the MC. Transcriptome and chromatin sequencing revealed COMPASS complex target genes in UPS, such as &lt;i>Cxcl10&lt;/i>, downregulated in the MC. Deleting &lt;i>Cxcl10&lt;/i> in non-MC cells increased their metastatic potential. Trea</pubmed_abstract><journal>iScience</journal><pubmed_title>The COMPASS complex maintains the metastatic capacity imparted by a subpopulation of cells in UPS.</pubmed_title><pmcid>PMC11233968</pmcid><funding_grant_id>R35 CA197616</funding_grant_id><funding_grant_id>R00 AR077685</funding_grant_id><funding_grant_id>R01 CA183811</funding_grant_id><funding_grant_id>R01 CA251407</funding_grant_id><funding_grant_id>2R35 CA197616</funding_grant_id><pubmed_authors>Nakagawa M</pubmed_authors><pubmed_authors>Browne M</pubmed_authors><pubmed_authors>Alman BA</pubmed_authors><pubmed_authors>Nadesan P</pubmed_authors><pubmed_authors>Ishikawa K</pubmed_authors><pubmed_authors>Guardino N</pubmed_authors><pubmed_authors>Tang J</pubmed_authors><pubmed_authors>Kirsch DG</pubmed_authors><pubmed_authors>Diao Y</pubmed_authors><pubmed_authors>Shimada E</pubmed_authors><pubmed_authors>Ou J</pubmed_authors><pubmed_authors>Martin JT</pubmed_authors><pubmed_authors>Puviindran V</pubmed_authors><pubmed_authors>Xiang Y</pubmed_authors><pubmed_authors>Ban GI</pubmed_authors><pubmed_authors>Wallace A</pubmed_authors></additional><is_claimable>false</is_claimable><name>The COMPASS complex maintains the metastatic capacity imparted by a subpopulation of cells in UPS.</name><description>Intratumoral heterogeneity is common in cancer, particularly in sarcomas like undifferentiated pleomorphic sarcoma (UPS), where individual cells demonstrate a high degree of cytogenic diversity. Previous studies showed that a small subset of cells within UPS, known as the metastatic clone (MC), as responsible for metastasis. Using a CRISPR-based genomic screen &lt;i>in-vivo&lt;/i>, we identified the COMPASS complex member &lt;i>Setd1a&lt;/i> as a key regulator maintaining the metastatic phenotype of the MC in murine UPS. Depletion of &lt;i>Setd1a&lt;/i> inhibited metastasis development in the MC. Transcriptome and chromatin sequencing revealed COMPASS complex target genes in UPS, such as &lt;i>Cxcl10&lt;/i>, downregulated in the MC. Deleting &lt;i>Cxcl10&lt;/i> in non-MC cells increased their metastatic potential. Trea</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jul</publication><modification>2026-06-01T07:03:28.078Z</modification><creation>2024-11-09T15:17:09.164Z</creation></dates><accession>S-EPMC11233968</accession><cross_references><pubmed>38989451</pubmed><doi>10.1016/j.isci.2024.110187</doi></cross_references></HashMap>